JP2015505533A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015505533A5 JP2015505533A5 JP2014552659A JP2014552659A JP2015505533A5 JP 2015505533 A5 JP2015505533 A5 JP 2015505533A5 JP 2014552659 A JP2014552659 A JP 2014552659A JP 2014552659 A JP2014552659 A JP 2014552659A JP 2015505533 A5 JP2015505533 A5 JP 2015505533A5
- Authority
- JP
- Japan
- Prior art keywords
- enzyme
- independently
- group
- btm
- biotargeting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 239000000556 agonist Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 1
- 125000006654 (C3-C12) heteroaryl group Chemical group 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- ABSNGNUGFQIDDO-UHFFFAOYSA-N 2-benzylguanidine Chemical compound NC(N)=NCC1=CC=CC=C1 ABSNGNUGFQIDDO-UHFFFAOYSA-N 0.000 description 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 1
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 150000004696 coordination complex Chemical group 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 125000005549 heteroarylene group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- FRIZVHMAECRUBR-UHFFFAOYSA-N iomazenil Chemical compound C1N(C)C(=O)C2=C(I)C=CC=C2N2C=NC(C(=O)OCC)=C21 FRIZVHMAECRUBR-UHFFFAOYSA-N 0.000 description 1
- 229950006634 iomazenil (123i) Drugs 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- XLRPYZSEQKXZAA-OCAPTIKFSA-N tropane Chemical compound C1CC[C@H]2CC[C@@H]1N2C XLRPYZSEQKXZAA-OCAPTIKFSA-N 0.000 description 1
- 229930004006 tropane Natural products 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1201062.5 | 2012-01-23 | ||
| GB201201062A GB201201062D0 (en) | 2012-01-23 | 2012-01-23 | Radiofluorination method |
| US201261589972P | 2012-01-24 | 2012-01-24 | |
| US61/589,972 | 2012-01-24 | ||
| PCT/EP2013/051154 WO2013110615A1 (en) | 2012-01-23 | 2013-01-22 | Radiofluorination method |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015505533A JP2015505533A (ja) | 2015-02-23 |
| JP2015505533A5 true JP2015505533A5 (https=) | 2017-03-02 |
| JP6609409B2 JP6609409B2 (ja) | 2019-11-20 |
Family
ID=45840808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014552659A Active JP6609409B2 (ja) | 2012-01-23 | 2013-01-22 | 放射性フッ素化方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11135322B2 (https=) |
| EP (1) | EP2806901B1 (https=) |
| JP (1) | JP6609409B2 (https=) |
| KR (1) | KR102046437B1 (https=) |
| CN (2) | CN104302327A (https=) |
| AU (1) | AU2013211639B2 (https=) |
| GB (1) | GB201201062D0 (https=) |
| WO (1) | WO2013110615A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201201062D0 (en) | 2012-01-23 | 2012-03-07 | Ge Healthcare Ltd | Radiofluorination method |
| GB201308053D0 (en) | 2013-05-03 | 2013-06-12 | Ge Healthcare Ltd | Metal complexes and fluorination thereof |
| EP3212610B1 (en) * | 2014-10-30 | 2020-10-28 | Katholieke Universiteit Leuven | Methods for low temperature fluorine-18 radiolabeling of biomolecules |
| JP7062977B2 (ja) * | 2018-01-30 | 2022-05-09 | 株式会社デンソーウェーブ | 複数の無線機器をグルーピングする方法 |
| CN113663621A (zh) * | 2020-05-14 | 2021-11-19 | 益诺思生物技术海门有限公司 | 一种89Zr药物标记及纯化装置及其方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8719041D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| US6183744B1 (en) | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US7597876B2 (en) * | 2007-01-11 | 2009-10-06 | Immunomedics, Inc. | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules |
| US7993626B2 (en) | 2007-01-11 | 2011-08-09 | Immunomedics, Inc. | Methods and compositions for F-18 labeling of proteins, peptides and other molecules |
| WO2006138357A1 (en) | 2005-06-14 | 2006-12-28 | The University Of Akron | Macrocyclic metal complexes for their use as anticancer agents |
| GB0524851D0 (en) * | 2005-12-06 | 2006-01-11 | Ge Healthcare Ltd | Radiolabelling method using polymers |
| CN101568352B (zh) * | 2007-01-11 | 2013-08-21 | 免疫医学股份有限公司 | 用于蛋白质、肽和其他分子的改进的f-18标记的方法和组合物 |
| WO2009035959A2 (en) | 2007-09-10 | 2009-03-19 | Ge Healthcare Limited | Radiofluorination methods |
| US8761016B2 (en) | 2008-03-28 | 2014-06-24 | Georgia Tech Research Corporation | Systems and methods for intelligent policy enforcement in access networks |
| KR101106433B1 (ko) | 2009-04-03 | 2012-01-18 | 서울대학교산학협력단 | 암 조직의 타겟팅을 위한 마크로사이클릭 아미노산 계열의 유도체 및 그의 방사성 또는 비방사성 금속 표지화합물 |
| AU2010326004B2 (en) * | 2009-12-04 | 2016-04-21 | Immunomedics, Inc. | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules |
| JP2013528180A (ja) | 2010-05-28 | 2013-07-08 | ジーイー・ヘルスケア・リミテッド | 放射性標識化合物及びその製造方法 |
| EP2651411B1 (en) * | 2010-12-13 | 2020-09-16 | Immunomedics, Inc. | Methods and compositions for improved f-18 labeling of proteins, peptides and other molecules |
| CN102391168B (zh) | 2011-09-16 | 2013-11-27 | 中山大学附属第一医院 | 对称性双功能偶联剂及其偶合分子显像剂 |
| GB201201062D0 (en) | 2012-01-23 | 2012-03-07 | Ge Healthcare Ltd | Radiofluorination method |
| GB201308053D0 (en) | 2013-05-03 | 2013-06-12 | Ge Healthcare Ltd | Metal complexes and fluorination thereof |
-
2012
- 2012-01-23 GB GB201201062A patent/GB201201062D0/en not_active Ceased
-
2013
- 2013-01-22 WO PCT/EP2013/051154 patent/WO2013110615A1/en not_active Ceased
- 2013-01-22 CN CN201380015583.9A patent/CN104302327A/zh active Pending
- 2013-01-22 EP EP13701070.8A patent/EP2806901B1/en active Active
- 2013-01-22 AU AU2013211639A patent/AU2013211639B2/en active Active
- 2013-01-22 KR KR1020147020360A patent/KR102046437B1/ko active Active
- 2013-01-22 CN CN201811135640.8A patent/CN109045312A/zh active Pending
- 2013-01-22 JP JP2014552659A patent/JP6609409B2/ja active Active
- 2013-01-22 US US14/373,413 patent/US11135322B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505533A5 (https=) | ||
| JP2019514426A5 (https=) | ||
| JP2014534220A5 (https=) | ||
| JP2024514844A5 (https=) | ||
| JP2012512907A5 (https=) | ||
| DK2678679T3 (en) | USE OF ACETYLATED TUBULIN AS A BIOMARKER FOR PHARMACEUTICAL RESPONSE TO FURAZANOBENZIMIDAZOLES | |
| JP2013507423A5 (https=) | ||
| JP2018531987A5 (https=) | ||
| JP2012509902A5 (https=) | ||
| Hoang et al. | Discovery of potent human glutaminyl cyclase inhibitors as anti-Alzheimer’s agents based on rational design | |
| JP2016502538A5 (https=) | ||
| EP2224912A4 (en) | IMPROVED COMPOSITIONS AND METHOD OF RELEASING NUCLEIC ACIDS | |
| JP2015518831A5 (https=) | ||
| JP2012503621A5 (https=) | ||
| JP2009542716A5 (https=) | ||
| EP3391898A3 (en) | Stapled and stitched polypeptides and uses thereof | |
| EP1085889A2 (en) | Novel therapeutic agents that modulate endothelin receptors | |
| ATE554085T1 (de) | Neue inhibitoren von glutaminylcyclase | |
| JP2012072144A (ja) | グレリンの類似体 | |
| JP2002510669A (ja) | 新規の局所麻酔組成物およびその使用 | |
| CY1118314T1 (el) | Συνδυασμοι αγωνιστων υποδοχεα σεροτονινης για την αγωγη κινητικων διαταραχων | |
| AR070465A1 (es) | Compuestos biciclicos con contenido de nitrogeno activos en condiciones de dolor cronicas | |
| US20160052882A1 (en) | Substituted 1-arylethyl-4-acylaminopiperidine derivatives as opioid/alpha-adrenoreceptor modulators and method of their preparation | |
| JP2010522214A5 (https=) | ||
| EP2551266A8 (en) | 2',2-dithiazol non-nucleoside compounds, preparation methods, pharmaceutical compositions and uses as hepatitis virus inhibitors thereof |